Search clinical trials for: Pandemic Influenza vaccine

Total 12029 results

GlaxoSmithKline

Recruiting

A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults

Influenza, Human

United States
Vaxine Pty Ltd
Australian Respiratory and Sleep Medicine Institute Ltd

Not yet recruiting

Covid-19 and Influenza Oral Vaccine Study

Influenza, Human | covid19 Infection

Australia
Pfizer

Recruiting

A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza

Influenza | Vaccines | Grippe

United States
Oslo University Hospital

Recruiting

H7HLAII DNA Influenza Vaccine (H7N9vax-1)

Influenza A | Pandemic Influenza

Norway
Chronic Obstructive Pulmonary Disease Trial Network...
The Novo Nordic Foundation

Not yet recruiting

Vaccine Pandemic Preparedness Through Airway Immunology Characterization (VAXXAIR)

Influenza, Human

United Kingdom, Denmark
Seqirus
Biomedical Advanced Research and Development Authority

Active, not recruiting

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults

Infections | Virus Diseases | Respiratory Tract Infections | Influenza, Human | Infection Viral

United States
Seqirus

Completed

A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine

Influenza, Human

Estonia, Philippines
ModernaTX, Inc.

Active, not recruiting

A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults

Influenza

United States
Paolo Corradini
University of Milan

Completed

Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic Patients

Lymphoma | Multiple Myeloma | Myeloproliferative Disease

Italy
Seqirus

Completed

A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed

Infections | RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases | Influenza, Human | Orthomyxoviridae Infections | Influenza in Birds

United States
Livzon Pharmaceutical Group Inc.

Active, not recruiting

Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III (COVID-19)

COVID-19 Pandemic

Philippines, Indonesia, Russian Federation
BlueWillow Biologics
National Institute of Allergy and Infectious Diseases (NIAID); University of...

Active, not recruiting

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults (IN-NE-rH5)

Influenza, Pandemic

United States
GlaxoSmithKline

Completed

Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age

Influenza | Influenza Vaccines

United States, Thailand, Canada
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Protective Mechanisms Against a Pandemic Respiratory Virus (SLVP024)

Influenza
Novartis
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects

Pandemic Influenza Disease

Finland, Germany
GlaxoSmithKline

Completed

Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age

Influenza

Thailand, Australia, Mexico, Costa Rica, Philippines, Colombia, Singapore, Brazil
Seqirus
Novartis Vaccines

Completed

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

Influenza

United States, Germany
GlaxoSmithKline

Completed

Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults

Influenza | Influenza Vaccines

Taiwan, Hong Kong, Thailand, Singapore
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

Pandemic Influenza

Switzerland, Belgium, Germany
GlaxoSmithKline

Completed

Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population

Influenza | Influenza Vaccines

Germany
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine

Avian Influenza | Immunisation

United States
Rebecca Cox
Haukeland University Hospital; European Commission

Completed

Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults (PANFLUVAC)

Healthy | Influenza

Norway
University of Bergen
Haukeland University Hospital

Completed

Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen (H1N1VAC)

Healthy

Norway
GlaxoSmithKline

Completed

Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or Older

Influenza

Japan
GlaxoSmithKline

Completed

Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)

Influenza | Influenza Vaccines

Germany
Takeda

Completed

A Phase 4 Post-marketing Study of Intramuscular Injections of BLB-750 in Healthy Adult Subjects

Pandemic Influenza Prevention

Japan
GlaxoSmithKline
Icahn School of Medicine at Mount Sinai

Completed

A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines

Immunologic Tests

United States
GlaxoSmithKline

Completed

Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age

Influenza

Belgium, Italy
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children

Influenza

Australia, Singapore
Vaxine Pty Ltd
Australian Respiratory and Sleep Medicine Institute; Flinders University

Completed

A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults (FLU003)

Influenza

Australia
PATH
Institute of Experimental Medicine, Russia; Research Institute of Influenza... and other collaborators

Completed

Safety Trial of Live Attenuated Influenza (H7N3) Vaccine

Influenza | Avian Influenza

Russian Federation
Seqirus
Biomedical Advanced Research and Development Authority

Completed

A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age

Avian Influenza

United States
Vical

Completed

Pandemic Influenza Plasmid DNA Vaccines (Needle-Free)

Influenza

United States
GlaxoSmithKline

Completed

Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)

Influenza

Spain
GlaxoSmithKline

Terminated

Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children

Influenza

Norway
Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects

Pandemic H5N1 Influenza

United States, Australia, New Zealand, Thailand
Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children

Pandemic H5N1 Influenza

United States, Thailand
PATH
Institute of Experimental Medicine, Russia; Microgen

Completed

Reactogenicity, Safety, and Immunogenicity of a Live Monovalent H5N2 Influenza Vaccine

Influenza

Russian Federation
Research Institute of Influenza, Russia
World Health Organization; Institute of Experimental Medicine, Russia; Joint...

Unknown

Reactogenicity, Safety and Immunogenicity of a LAIV А/17/Hong Kong/2017/75108 H7N9 Influenza Vaccine

Vaccine Adverse Reaction
GlaxoSmithKline

Completed

Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children

Influenza

Spain
GlaxoSmithKline

Terminated

Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Children

Influenza

Czechia
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults

Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years

Influenza

United States, Canada
Shanghai Institute Of Biological Products

Completed

The Long-term Immunogenicity of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine

Influenza

China
GlaxoSmithKline

Completed

Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old

Influenza

Korea, Republic of
GlaxoSmithKline

Completed

Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years Old

Influenza

Thailand, Philippines
GlaxoSmithKline

Completed

Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults

Influenza

United States
GlaxoSmithKline

Completed

A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine.

Influenza

Taiwan
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine

Influenza

Japan
GlaxoSmithKline

Completed

Safety and Immunogenocity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Japanese Children

Influenza

Japan

3

Subscribe